Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.

Molecular cancer therapeutics - 1 Jul 2016

Awuah Prince, Bera Tapan K, Folivi Messan, Chertov Oleg, Pastan Ira

Abstract excerpt

Mesothelin (MSLN) is a differentiation antigen that is highly expressed in many epithelial cancers. MSLN is an important therapeutic target due to its high expression in cancers and limited expression in normal human tissues. Although it has been assumed that shed antigen is a barrier to immunotoxin action, a modeling study predicted that shed MSLN may enhance the action of MSLN-targeting recombinant immunotoxins...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Cell Membrane

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Neoplasm

Share to GPI-Linked Proteins

Share to Immunotoxins

Share to Recombinant Fusion Proteins

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27196771
DOI: 10.1158/1535-7163.MCT-15-0863
PMCID: PMC4936933

Genes

MSLN
TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.PMID 27196771Read ↗

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.Semantic proximity Read ↗

MesothelinSemantic proximity Read ↗

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.Semantic proximity Read ↗

Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights.Semantic proximity Read ↗

Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.Semantic proximity Read ↗

Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.Semantic proximity Read ↗

Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugationSemantic proximity Read ↗

Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.Semantic proximity Read ↗

A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumorsSemantic proximity Read ↗

Mesothelin-Specific CAR T Cells Target Ovarian Cancer.Semantic proximity Read ↗

Discovery of a novel human antibody VH domain with potent activity against mesothelin expressing cancer cells in both CAR T-cell and antibody drug conjugate formatsSemantic proximity Read ↗

DSG2-Directed CAR-T Cells Safely and Universally Eliminate Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.